Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TTR | P02766 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | TPMT | P51580 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4248118 | 0.88 | TPMT (0.57) | LMNAALDH1A1MAPTRAF1HPGD | |
| SCHEMBL19436450 | 0.88 | MAPT (0.50) | LMNAALDH1A1MAPTRAF1HPGD | |
| SCHEMBL1458078 | 0.86 | VCAM1 (0.49) | LMNAALDH1A1MAPTRAF1HPGD | |
| SCHEMBL11389414 | 0.85 | VCAM1 (0.50) | LMNAALDH1A1MAPTRAF1HPGD | |
| SCHEMBL7370467 | 0.84 | TPMT (0.56) | LMNAALDH1A1MAPTMAPK1MEN1 | |
| SCHEMBL24084153 | 0.84 | ALDH1A1 (0.55) | ALDH1A1MAPTHPGDMAPK1MEN1 | |
| SCHEMBL5598228 | 0.83 | LMNA (0.66) | LMNAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL31059025 | 0.83 | LMNA (0.66) | LMNAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL31059024 | 0.83 | LMNA (0.66) | LMNAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL25255894 | 0.81 | KMT2A (0.50) | LMNAALDH1A1MAPTHPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170119750-A1 | 2- (AZAINDOL-2-YL) BENZIMIDAZOLES AS PAD4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2017-05-04 | — | — | US | disclosed |
| US-9518054-B2 | 2-(azaindol-2-yl) benz imidazoles as PAD4 inhibitors | GLAXO GROUP LIMITED (GB) | 2016-12-13 | — | — | US | disclosed |
| US-20160009716-A1 | 2 - (AZAINDOL-2-YL) BENZ IMIDAZOLES AS PAD4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2016-01-14 | — | — | US | disclosed |
| US-9127003-B2 | 2-(azaindol-2-yl)benzimidazoles as PAD4 inhibitors | GLAXO GROUP LIMITED (GB) | 2015-09-08 | — | — | US | disclosed |
| US-20150175600-A1 | 2-(AZAINDOL-2-YL)BENZIMIDAZOLES AS PAD4 INHIBITORS | Glaxo Group Limited a corporation | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009716-A1 | 2 - (AZAINDOL-2-YL) BENZ IMIDAZOLES AS PAD4 INHIBITORS | PADI1, PADI4, PADI2 | LMNA 2575/4885ALDH1A1 112/4885MAPT 4884/4885 |
| US-20150175600-A1 | 2-(AZAINDOL-2-YL)BENZIMIDAZOLES AS PAD4 INHIBITORS | PADI1, PADI4, PADI2 | LMNA 2635/4885ALDH1A1 77/4885MAPT 4883/4885 |
| US-20170119750-A1 | 2- (AZAINDOL-2-YL) BENZIMIDAZOLES AS PAD4 INHIBITORS | PADI1, PADI4, PADI2 | LMNA 2458/4885ALDH1A1 77/4885MAPT 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.